
Pfizer has agreed to pay $345 million to resolve claims by consumers who claim they overpaid for EpiPens due to anticompetitive practices by the drugmaker and Mylan, the company that markets the emergency allergy treatment.
#Pfizer #Mylan #EpiPen #News #Reuters
Subscribe: http://smarturl.it/reuterssubscribe
Reuters brings you the latest business, finance and breaking news video from around the globe. Our reputation for accuracy and impartiality is unparalleled.
Get the latest news on: http://reuters.com/
Follow Reuters on Facebook: https://www.facebook.com/Reuters
Follow Reuters on Twitter: https://twitter.com/Reuters
Follow Reuters on Instagram: https://www.instagram.com/reuters/?hl=en
reutersbusinessfinance
0 Comments